These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 15040534)

  • 1. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost effectiveness analysis of highly active antiretroviral therapy in HIV asymptomatic patients].
    Pinto JL; López Lavid C; Badia X; Coma A; Benavides A
    Med Clin (Barc); 2000; 114 Suppl 3():62-7. PubMed ID: 10994566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HIV resistance testing. Introduction of a new technique].
    Dragsted UB; Benfield TL
    Ugeskr Laeger; 2002 Apr; 164(17):2263-7. PubMed ID: 11989174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996].
    Le Pen C; Rozenbaum W; Downs A; Lilliu H; Maurel F; Foucher F
    Therapie; 2002; 57(1):27-33. PubMed ID: 12090143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment adherence improves outcomes and manages costs.
    Valenti WM
    AIDS Read; 2001 Feb; 11(2):77-80. PubMed ID: 11279875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic burden and clinical course of HIV infection and AIDS today: how the variation of natural history, available treatments, and strictly related costs play a role in needs of health care].
    Manfredi R; Calza L; Gramegna A; Bocchi F; Fiacchi P; Corsini D; Chiodo F
    Recenti Prog Med; 2001 Nov; 92(11):648-54. PubMed ID: 11765655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
    Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
    Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impact of delaying or preventing AIDS in persons with HIV.
    Pinkerton SD; Holtgrave DR
    Am J Manag Care; 1999 Mar; 5(3):289-98. PubMed ID: 10351025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined antiviral treatment in HIV infection. Is it value for money?
    Davies D; Carne C; Camilleri-Ferrante C
    Public Health; 1999 Nov; 113(6):315-7. PubMed ID: 10637527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost of antiretroviral drug resistance in HIV-positive patients.
    Krentz HB; Ko K; Beckthold B; Gill MJ
    Antivir Ther; 2014; 19(4):341-8. PubMed ID: 24296618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV drug resistance and implications for the introduction of antiretroviral therapy in resource-poor countries.
    Petrella M; Brenner B; Loemba H; Wainberg MA
    Drug Resist Updat; 2001 Dec; 4(6):339-46. PubMed ID: 12030782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The affordability of antiretroviral therapy in developing countries: what policymakers need to know.
    Forsythe SS
    AIDS; 1998; 12 Suppl 2():S11-8. PubMed ID: 9792357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future issues in the treatment of HIV-1 infection.
    Matsushita S
    Int J Hematol; 2000 Jul; 72(1):20-7. PubMed ID: 10979204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?].
    Stoll M; Claes C; Schulte E; Körner T; von der Schulenburg JM; Schmidt R
    MMW Fortschr Med; 2000 Mar; 142 Suppl 1():45-9. PubMed ID: 10863311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcoidosis after antiretroviral therapy in a patient with acquired immunodeficiency syndrome.
    Gomez V; Smith PR; Burack J; Daley R; Rosa U
    Clin Infect Dis; 2000 Nov; 31(5):1278-80. PubMed ID: 11073764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effectiveness of HAART. Good planning assures long-term success].
    Manegold C
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():4-6. PubMed ID: 12043072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive HIV treatment cost-effective.
    Healthc Benchmarks; 1998 Aug; 5(8):128-9. PubMed ID: 10182003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of HIV-infections: success or crisis?].
    Pokrovskiĭ VV
    Ter Arkh; 2001; 73(11):52-4. PubMed ID: 11806206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.